Pascal Prigent News Today

Lille , Cambridge , Zurich , May 29, 2024 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage...

Extra-Financial Performance Report 2024 2023 Activity ...

Lille , Cambridge , Zurich , April 25, 2024 - GENFIT , a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced...

Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical...

Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 millionTopline interim...

US Food and Drug Administration has granted Priority Review for New Drug Application for elafibranor in PBC, and European Medicine Agency has also validated the Marketing Authorization Application ...

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in June 2023, paving the way to: a potential submission to the

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in...

Agreement gives Ipsen global1 rights to develop and commercialize GENFITs late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis ...